FDA To Lower Scrutiny Of CMV Tests Used In Transplant Patients
Executive Summary
A proposed rule from the US agency would move the in vitro diagnostics from high-risk class III to class II with special controls, eliminating the requirement for a PMA.
You may also be interested in...
US FDA Panel To Meet on Transplant IVDs, Test For Managing Antibiotics
The agency's microbiology devices advisory panel will hold a two-day meeting next month focused on classification of transplant IVDs and potential 510(k) requirements for a test that can help detect and monitor sepsis and other bacterial infection.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.